Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Update

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the target of a significant drop in short interest during the month of September. As of September 15th, there was short interest totaling 9,400 shares, a drop of 38.2% from the August 31st total of 15,200 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Basilea Pharmaceutica to a “hold” rating in a report on Wednesday, September 24th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Basilea Pharmaceutica has an average rating of “Hold”.

Basilea Pharmaceutica Price Performance

BPMUF opened at $67.75 on Tuesday. Basilea Pharmaceutica has a 12-month low of $47.50 and a 12-month high of $67.75. The firm has a 50 day moving average of $67.62 and a two-hundred day moving average of $58.60.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.